CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT04626752 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

UNKNOWN

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed or Refractory Multiple Myeloma

Interventions

DRUG: BCMA CAR-T
DRUG: Fludarabine
DRUG: Cyclophosphamide

Sponsor

Hebei Senlang Biotechnology Inc., Ltd.